Late Stabilization & Maintenance Phase of Treatment.

Slides:



Advertisements
Similar presentations
Medication-Assisted Therapy
Advertisements

1 setting standards for prescribing Dr Keron Fletcher.
Oxford University Hospitals NHS Trust Injectable medicines study day:
Dose Escalating Safety Study of a New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, in Patients Undergoing Total Hip Replacement: BISTRO I Eriksson.
International meeting
Managing the Mental Health Merry Go Round Karalyn Huxhagen B Pharm FPS AACPA.
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Client satisfaction and perceptions of treatments in the North American Opiate Medication Initiative Kirsten Marchand, MSc Candidate at UBC SPPH Canadian.
Pharmacological Treatment of Opioid Dependence during Pregnancy: Methadone and Buprenorphine Overview Karol Kaltenbach, PhD Maternal Addiction Treatment.
Effective Risk Management Strategies in Outpatient Methadone Treatment: Clinical Guidelines and Liability Prevention Curriculum MODULE 5 Take-Home Medication.
TB Presentation for Healthcare Students
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Purpose To determine whether metoprolol controlled/extended release
Injectable Opioid Treatment in England Clinical Experience Rob van der Waal.
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
Withdrawal From Treatment. 3 Situations 1. Voluntary – patient and doctor agree it is time to taper and try to stop treatment 2. Voluntary – patient insists.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
Stapleford-Athens 2011 International Addiction Conference Developing a rehab program with NTX as one entry requirement Dr George O’Neil
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.
HIV/AIDS Presented by Kunphen center for substance dependence and HIV/AIDS.
Substance Abuse Treatment. PROFILE OF A DRUG ABUSER  MOST PEOPLE IN TREATMENT ARE BETWEEN YEARS OF AGE  MANY DRUG ABUSERS SUFFER FROM MENTAL HEALTH.
Counseling, Informed consent, and Patient Rights in “See and Treat” Program.
Clinical Therapeutics Naltrexone for the Management of Alcohol Dependence Raymond F. Anton, M.D. N Engl J Med Volume 359(7): August 14, 2008.
Comparison of Nilotinib and Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year Larson.
VIOLENCE PREVENTION AND INTERVENTION PROGRAM (VPIP) TECHNIQUES TO PREVENT DATING VIOLENCE I. Indicators of Perpetrators and Victims of Dating Violence.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
1 Assessing and Improving ARV Adherence HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Intensive Residential Treatment (Level III.7, III.5) Long Term Residential Treatment (Level III.3, III.1) Intensive Outpatient Treatment (Level II.1)
FIVE MINUTES TO MAKE A DIFFERENCE Presentation by: Mark Barnes.
Hypertension: Blood Pressure Measurement and the new NICE guideline Prof Richard McManus BHS Annual Meeting Cambridge 2011 NICE clinical guideline 127.
Pain Management Laura Bergs FNP. Definition of Chronic Pain Anyone with pain greater than 3 months Anyone with pain greater than 3 months Pain An unpleasant.
Drugs in the Body (1) Recurrence Relations A patient is given an initial dose of 50mg of a drug. Each hour the patient is given a 20mg tablet of the.
Preface for Screening Questions  These questions help me to provide the best possible care.  You do not have to answer them if you are uncomfortable.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Abstinence Incentives for Methadone Maintained Stimulant Users: Outcomes for Those Testing Stimulant Positive vs Negative at Study Intake Maxine L. Stitzer.
1 Controlled drug release Dr Mohammad Issa. 2 Frequency of dosing and therapeutic index  Therapeutic index (TI) is described as the ratio of the maximum.
Tom Waddell Urban Health Clinic: Patients Using Controlled Medicines* If you are taking controlled medicines, your safety is our highest priority! Our.
Therapeutic Drug Monitoring (TDM) Sticker Project A New Method for Documenting Times of Medication Doses and Drug Levels.
Question 1 Pozen estimated an annual incidence of tardive dyskinesia (TD) of up to 0.038% for metoclopramide at a daily dose of mg/day for 72 days/year.
Don Teater MD Medical Advisor National Safety Council Itasca, IL Medical Provider Behavioral Health Group Asheville, NC Medical Provider Meridian Behavioral.
Clinical Management Course: Medical Complications of Alcoholism Peter R. Martin, M.D. Professor of Psychiatry and Pharmacology.
Weaning off BENZODIAZEPINES After Long-Term Use By Dr Sadaf Cheema GPST2.
Teresa Meenaghan RANP Haematology 16thOctober HAI.
Clinical Pharmacokinetics of Alcohol in A CDAT Sample Robert Cohen Consultant Addiction Psychiatrist
After the ED Alcohol & Drug Treatment Options Dr Mark Daglish Director of Addiction Psychiatry Royal Brisbane & Women’s Hospital.
Detox workshop Susanna Lawrence October Aim and objectives  Create consistent, evidence based process for opiate, alcohol and benzodiazepine detoxes.
Provider Initiated HIV Counseling and Testing Unit 2: Introduction and Rational for PIHCT.
Benjamin Nordstrom MD, PhD VP, Medical Director for Program Development Phoenix House Foundation.
Specialist service provision. Who is involved in specialist services? Statutory services –Run by NHS and Social Care, these deliver medical and psychosocial.
Terms Related to Substance Abuse
What does pharmacology have to do with treatment of heroin addiction?
Omitted, Delayed or Early Medication Doses
Section 27: Cognitive Behavioral Therapy I
Module 4 (a) Getting started on PrEP
Controlled drug release
Addressing sleep problems- The role of long-acting opioids
Here Is Some More About Drug Addiction Treatment
How Sober Living Homes Can Help You
Other drugs used in the treatment of bipolar disorder
Treatments for Addiction
Warfarin Prescribing.
considering further dose(s)
به نام آنكه هستي نام ازويافت فلك جنبش.زمين آرام ازويافت
University of Nizwa College of Pharmacy and Nursing School of Pharmacy
Guidelines for Initiation of Therapy
Thrombophilia in pregnancy: Whom to screen, when to treat
Guideline for the Treatment of Alcohol Use Disorder in the Outpatient Setting with Intramuscular Naltrexone Assess Candidacy for IM Naltrexone Meets DMS-V.
Medication Assisted Treatment of Opioid Use Disorder
Presentation transcript:

Late Stabilization & Maintenance Phase of Treatment

Challenges in stabilization Management with higher doses “Carries”

Dose Adjustment Usual dose is mg Higher doses sometimes needed Consider a trough blood level if dose is going higher than 120mg or if there is uncertainty about the clinical picture of withdrawal symptoms Trough level - therapeutic range is ng/ml

Rapid Metabolisers ‘I feel sleepy in the afternoon but I’m in withdrawal by nightime’ Peak blood level drawn 4 hours after witnessed drink Trough level drawn 24 hours after last dose Peak:trough >than 2:1 Dose may need to be split - twice daily dosing

Management of High Doses Risk of cardiac effects with doses higher than mg Prolonged QT interval - risk of arrythmia ECG should be done at this time & should be repeated with subsequent dose increases

“Carries” Take - home doses can be given when –At least 2 months in treatment –Clinical Stability is demonstrated –Client is able to store Methadone safely in a locked box Must consider patient safety & public safety when deciding to give carries

Clinical Stability This is more than just providing negative urine drug screens Methadone dose is stable Elimination of sustained problematic drug or alcohol use Emotionally stable Housing, employment or school &/or a stable support system Adherence to the treatment agreement

Schedule of increasing Carries After the first 2 months in treatment carries can be increased by 1 additional take-home dose/month Maximum of 6 carries/week - only 1 witnessed drink at the pharmacy per week

Counseling Once withdrawal symptoms have been controlled, clients can benefit from counseling Residential or out-patient rehab programs, 1:1 counseling & 12 step support groups Clients usually have multiple social & emotional issues to resolve